Aurobindo Pharma Limited has informed the Exchange regarding a press release dated May 13, 2025, titled "CuraTeQ Biologics receives approval for biosimilar Zefylti from UK s MHRA".
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma's wholly owned step-down subsidiary CuraTeQ Biologics has received marketing authorization from the UK's MHRA for Zefylti, its filgrastim biosimilar. This comes shortly after Zefylti received European Commission approval in February 2025. Zefylti is CuraTeQ's second biosimilar approved by the MHRA, following Bevqolva in December 2024. CuraTeQ is headquartered in Hyderabad and has a pipeline of 14 biosimilars focused mainly on oncology and immunology. The UK approval gives Aurobindo another regulated market entry for its biosimilar portfolio, building on its existing presence in over 150 countries.
Positive signal for the stock — another regulatory approval in a major market (UK) strengthens Aurobindo's biosimilar business and adds a new revenue stream, complementing the recent EU approval and its growing Bevqolva franchise.